Fat Blaster
526 mg declared across 7constituents. Composition is the supplier’s, not a laboratory measurement.
Fat Blaster (LC526) is a 10 mL injectable solution carrying 526 mg of seven separate nutrients: L-carnitine 300 mg, inositol 50 mg, choline 50 mg, vitamin B6 (pyridoxine) 50 mg, NADH 50 mg, methionine 25 mg and vitamin B12 (cyanocobalamin) 1 mg. Methionine, inositol and choline are the classical lipotropic trio, a product category old enough to have been the subject of a Medical Letter therapeutics review in 1973. A search of the indexed literature returns no controlled trial of this formulation, of this seven-constituent combination, or of a methionine-inositol-choline injection with or without B12. Everything below is evidence for individual constituents, almost entirely given by mouth and at exposures far above the milligrams present here, and none of it transfers automatically to the mixture.
Information on this page is provided for laboratory research reference. The compound is not a drug, supplement, or medical product, and is not for human or veterinary use, ingestion, or consumption.
No reviewed report has been published for this product family yet. The molecular values opposite are public reference data, not results measured on a CRX sample.
Browse published reports →The constituents act on unrelated pathways. L-carnitine is required to carry long-chain fatty acids across the inner mitochondrial membrane for beta-oxidation, and is accumulated by cells through the OCTN2 transporter. Choline, by way of betaine, is the methyl donor in a pathway parallel to folate for remethylating homocysteine to methionine, which is why choline depletion raises post-methionine-load homocysteine. Pyridoxine is a vitamin B6 form whose activation depends on pyridoxal kinase. NADH is the reduced form of nicotinamide adenine dinucleotide. No published mechanism links the seven together as an administered blend, and none of these pathways has been shown to be rate-limited by injected milligram quantities in a nutrient-replete person.3,4,5,6
Fat loss & metabolism
Pooled across nine randomized controlled trials of oral carnitine supplementation in adults (total n = 911), carnitine groups lost 1.33 kg more weight than control groups (95% CI -2.09 to -0.57) and showed a BMI difference of -0.47 kg/m2 (95% CI -0.88 to -0.05). Meta-regression found the weight-loss advantage shrank significantly as trial duration lengthened (p = 0.002).7
In a meta-analysis of 37 randomized controlled trials in adults (n = 2,292), oral l-carnitine lowered body weight 1.21 kg (95% CI -1.73 to -0.68) and fat mass 2.08 kg (95% CI -3.44 to -0.72) versus control, with no significant effect on waist circumference or body fat percent. Restricted to high-quality trials, only the body-weight effect held. Dose-response modelling put the maximum at oral ingestion of 2,000 mg daily.8
A systematic review screened 20,504 citations and identified 315 randomized controlled trials of 14 purported dietary supplements and alternative therapies for weight loss in adults aged 18 and over. Only 52 of the 315 trials (16.5%) were rated low risk of bias with data sufficient to support efficacy, and of those 52, just 16 (31%) reported a significant between-group weight difference against their comparator, ranging from 0.3 to 4.93 kg.2
In a meta-analysis of seven randomized controlled trials of oral myo-inositol in pregnant women, myo-inositol reduced the incidence of gestational diabetes against control (OR 0.32, 95% CI 0.15 to 0.72) and lowered 2-hour OGTT glucose (MD -5.29, 95% CI -10.24 to -0.34), with no significant effect on birth weight. The outcome was glucose tolerance in pregnancy, not weight or fat loss, and the authors qualify the recommendation for heterogeneity.9
In a randomized placebo-controlled trial of 15 choline-deficient adults on home parenteral nutrition, the 7 given 2 g choline chloride in the intravenous feed gained 13.3 Hounsfield units of liver CT density at four weeks versus 5.8 in the 8 unsupplemented (p = 0.04), indicating less liver fat, with ALT falling versus placebo through week 24. Steatosis returned ten weeks after withdrawal. No body-weight or fat outcome was measured.10
Two hours after an oral methionine load used as a metabolic challenge, choline-deficient C57BL/6J mice had plasma homocysteine twice that of choline-fed mice. In a pilot of 8 men fed a near-choline-free diet until clinically choline-depleted or for up to 42 days, homocysteine four hours after the same load ran 35% higher than when the men were choline-replete. Methionine was the probe here, not a treatment.4
A review of carnitine transport describes carnitine as essential for moving long-chain fatty acids across the inner mitochondrial membrane for beta-oxidation, with cellular uptake via OCTN2. Humans with recessive OCTN2 defects develop primary carnitine deficiency, presenting early with hypoketotic hypoglycaemia and hepatic encephalopathy or later with cardiac and skeletal myopathy, and responding to oral carnitine. The review addresses this genetic disorder, not supplementation in carnitine-replete people.3
Focus & brain health
In a 12-week randomized, double-blind, placebo-controlled trial in 207 adults with myalgic encephalomyelitis/chronic fatigue syndrome, the 104 given oral coenzyme Q10 200 mg plus NADH 20 mg daily showed within-group falls from baseline in cognitive fatigue perception and total FIS-40 score (p < 0.001 and p = 0.022) — changes within the treated arm over time, not against the 103 on placebo. NADH was never given alone.6
In a 24-month randomized trial of 31 adults meeting CDC criteria for chronic fatigue syndrome, the 12 assigned oral NADH had a significantly lower mean symptom score in the first trimester than those assigned nutritional supplements plus psychological therapy (p < 0.001), but scores were similar between groups in every subsequent trimester. The comparator was active therapy rather than placebo, and the NADH arm held 12 people.11
A meta-analysis of 16 randomized controlled trials (n = 6,276) in patients without overt vitamin B12 deficiency or advanced neurological disorders found no effect of oral vitamin B12 alone, or of B12 plus folic acid with or without vitamin B6, on any subdomain of cognitive function, and no overall effect on measures of depression, against comparator. Only one trial reported idiopathic fatigue, too few to pool.12
What investigators recorded alongside the results above, at the rates their papers state.
Sensory peripheral neuropathy from excess pyridoxine. A review of vitamin B-6 toxicity reports that cases of adverse effects have increased alongside use of pyridoxine-containing supplements, and that excessive intake injures sensory neurons preferentially, plausibly through inhibition of pyridoxal kinase. This vial contains 50 mg of pyridoxine, and the evidence base is case reports and mechanistic study rather than a controlled dose-response.5
as reported; case-based, no incidence rate given
Long-term safety of carnitine is not established above the assessed level. A risk assessment identified an observed safe level of 2,000 mg per day of l-carnitine equivalents for chronic oral supplementation and judged the data above that insufficient for a confident conclusion of long-term safety. That assessment was derived for oral supplementation, so it does not transfer to an injected route; this vial contains 300 mg of L-carnitine.13
as reported; no upper level derivable from existing trial data
Conversion of L-carnitine to trimethylamine-N-oxide. Chronic dietary L-carnitine raised TMAO and accelerated atherosclerosis in mice unless the intestinal microbiota was concurrently suppressed, and among 2,595 humans undergoing cardiac evaluation, plasma carnitine predicted prevalent cardiovascular disease and incident myocardial infarction, stroke or death, but only in those with concurrently high TMAO. The conversion step described is gut-microbiota-dependent and was driven by dietary intake, while the human association was with plasma carnitine concentration.14
as reported; human risk confined to subjects with concurrently high TMAO
No controlled safety or efficacy data exist for this blend, for a methionine-inositol-choline injection with or without B12, or for these constituents administered together by this route. A search of the indexed literature returns no such trial. The absence is itself the entry: lipotropic products have been commercially available at least since they were reviewed in Medical Letter in 1973, and the surrounding weight-loss supplement literature is dominated by trials at high risk of bias.1,2
not established; no controlled trial of this formulation identified
- 1.Lipotropic products. · The Medical letter on drugs and therapeutics · 1973 · PMID 4123340
- 2.A Systematic Review of Dietary Supplements and Alternative Therapies for Weight Loss. · Obesity (Silver Spring) · 2021 · PMID 34159755
- 3.Carnitine transport and fatty acid oxidation. · Biochimica et Biophysica Acta · 2016 · PMID 26828774
- 4.Choline deficiency in mice and humans is associated with increased plasma homocysteine concentration after a methionine load. · The American Journal of Clinical Nutrition · 2005 · PMID 15699233
- 5.Vitamin B-6-Induced Neuropathy: Exploring the Mechanisms of Pyridoxine Toxicity. · Advances in Nutrition · 2021 · PMID 33912895
- 6.Effect of Dietary Coenzyme Q10 Plus NADH Supplementation on Fatigue Perception and Health-Related Quality of Life in Individuals with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial. · Nutrients · 2021 · PMID 34444817
- 7.The effect of (L-)carnitine on weight loss in adults: a systematic review and meta-analysis of randomized controlled trials. · Obesity Reviews · 2016 · PMID 27335245
- 8.Effects of l-carnitine supplementation on weight loss and body composition: A systematic review and meta-analysis of 37 randomized controlled clinical trials with dose-response analysis. · Clinical Nutrition ESPEN · 2020 · PMID 32359762
- 9.Myo-inositol supplementation for the prevention of gestational diabetes: A meta-analysis of randomized controlled trials. · European Journal of Obstetrics & Gynecology and Reproductive Biology · 2022 · PMID 35460931
- 10.Choline deficiency causes reversible hepatic abnormalities in patients receiving parenteral nutrition: proof of a human choline requirement: a placebo-controlled trial. · JPEN Journal of Parenteral and Enteral Nutrition · 2001 · PMID 11531217
- 11.Comparison of oral nicotinamide adenine dinucleotide (NADH) versus conventional therapy for chronic fatigue syndrome. · Puerto Rico Health Sciences Journal · 2004 · PMID 15377055
- 12.Effects of Vitamin B12 Supplementation on Cognitive Function, Depressive Symptoms, and Fatigue: A Systematic Review, Meta-Analysis, and Meta-Regression. · Nutrients · 2021 · PMID 33809274
- 13.Risk assessment for carnitine. · Regulatory Toxicology and Pharmacology · 2006 · PMID 16901595
- 14.Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. · Nature Medicine · 2013 · PMID 23563705